CRISM Therapeutics Corporation (AIM:CRTX)

CRISM Therapeutics Cash Flow Statement

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-7.51	-7.57	-2.5	-0.89	-1.95	-1.76
Depreciation & Amortization	-	-	-	0.2	0	0
Other Operating Activities	4.78	5.11	-0.4	-0.67	0.34	0.32
Operating Cash Flow	-2.56	-2.17	-2.92	-1.35	-1.61	-1.44
Capital Expenditures	0	-	-	-0.31	-0.41	-0.38
Divestitures	-	-	-	4.53	-	-
Other Investing Activities	27.64	27.42	-0.42	0.24	0.03	0
Investing Cash Flow	30	27.42	-0.42	4.46	-3.79	-0.38
Short-Term Debt Issued	-	-	-	-	0.44	0.37
Total Debt Issued	-	-	-	-	0.44	0.37
Short-Term Debt Repaid	-	-	-	-	-0.53	-0.63
Total Debt Repaid	-	-	-	-	-0.53	-0.63
Net Debt Issued (Repaid)	-	-	-	-	-0.08	-0.26
Issuance of Common Stock	0.1	-	0.29	-	7.33	1.39
Common Dividends Paid	-24.88	-24.69	-	-	-	-
Other Financing Activities	-	-	0.52	-	-	-
Financing Cash Flow	-24.78	-24.69	0.8	-	7.25	1.13
Foreign Exchange Rate Adjustments	-0.09	0.04	-	-0.23	-0.09	0.03
Net Cash Flow	2.57	0.6	-2.54	2.87	1.75	-0.65
Free Cash Flow	-2.56	-2.17	-2.92	-1.67	-2.02	-1.81
Free Cash Flow Per Share	-0.22	-0.25	-0.34	-0.19	-0.30	-0.40
Cash Interest Paid	-	-	-	-	-	0.01
Levered Free Cash Flow	-3.42	18.29	-1.91	-18.57	-1.42	-1.67
Unlevered Free Cash Flow	-3.42	18.29	-1.91	-18.57	-1.42	-1.33
Change in Net Working Capital	2.28	-19.31	0.75	17.71	-0.05	0.02

Source: S&P Global Market Intelligence. Standard template. Financial Sources.